Hangry No More: Mood Stability on GLP-1 Medications

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

You know the feeling. It's 4:15 in the afternoon, lunch was six hours and half a granola bar ago, and someone asks you a completely reasonable question. You snap at them. Then you feel bad about snapping, which somehow makes the irritation worse, and the whole thing keeps spiraling until you finally eat something and the world quietly reassembles itself.

That's hangry. Every one of us has been there. What surprises people is how often it comes up in my weight loss consults at Magnolia Functional Wellness, and not in the direction you'd expect. Patients three months into a GLP-1 medication will tell me, almost as an afterthought, that they stopped yelling at their kids in the carpool line. Their spouse noticed before they did. And then they ask the obvious question: is that the medication, or is that just what happens when you finally lose thirty pounds?

It's a good question, and the honest answer is more complicated than either the enthusiasts or the alarmists want it to be. There's real research on GLP-1 medications and mood. Some of it is reassuring. Some of it isn't. And most of what I actually see in clinic, the day to day mood complaints that bring people back into my office, has less to do with the drug's effect on the brain than with what patients are doing (or not doing) at the dinner table.

What "Hangry" Actually Is

Hangry isn't a character flaw. It's a predictable physiologic state, and understanding the mechanics helps explain why GLP-1 medications change it.

When blood glucose drops, your body doesn't politely wait for you to find a sandwich. It mounts a counter-regulatory response. Glucagon goes up to pull stored glucose out of the liver. Cortisol rises. And critically, so does adrenaline. That last one is why hangry feels the way it does: jittery, short-fused, faintly panicked. You are, in a small and temporary way, in a stress response. Your body has decided this is an emergency, and it has flooded you with the chemistry of an emergency.

Meanwhile the brain is running low on its preferred fuel. Your brain is roughly two percent of your body weight and consumes something like twenty percent of your energy, and the prefrontal cortex, the part that handles impulse control, patience, and thinking before speaking, is metabolically expensive. It's also the first thing to go offline when resources get scarce. The amygdala, which handles threat and irritation, is much cheaper to run and keeps humming along just fine. So you end up with the alarm system fully powered and the brakes browning out. Of course you snap at people.

Layer on top of that the hunger signaling itself. Ghrelin climbs the longer you go without eating. Neuropeptide Y rises in the hypothalamus, driving food-seeking behavior. What patients describe to me as "food noise," that relentless background chatter about what and when they're going to eat next, is this system doing exactly what it evolved to do. It's just doing it in an environment where nobody is actually starving, and where the noise mostly gets in the way.

Here's the part I want you to hold onto: irritability during weight loss is not weakness. It's what a hungry, glucose-starved, adrenaline-soaked brain produces. Which means it's something we can address with physiology instead of willpower.

How GLP-1 Medications Change That Cycle

Semaglutide and tirzepatide work on several systems at once, and a few of them bear directly on mood stability.

The first is gastric emptying. These medications slow the rate at which food leaves your stomach, which flattens the glucose curve after a meal. Instead of the spike and the crash, you get a gentler rise and a gentler fall. No crash means no counter-regulatory adrenaline surge, and no adrenaline surge means the 4:15 snap doesn't happen. For a lot of patients this alone accounts for most of the mood improvement they notice.

The second is how these drugs handle insulin. GLP-1 receptor agonists stimulate insulin release in a glucose-dependent way, meaning the effect scales with how high your blood sugar actually is and largely switches off when glucose is normal. That's a meaningful design feature. On their own, in someone without diabetes and not taking insulin or a sulfonylurea, these medications aren't driving you into hypoglycemia. They're also suppressing glucagon after meals, which further smooths the whole curve.

The third is central. GLP-1 receptors aren't confined to the pancreas and gut. They're expressed in the hypothalamus, the brainstem, and in reward-related regions. That's why appetite suppression on these medications feels qualitatively different from white-knuckling a diet. The signal to stop eating arrives on its own instead of being manufactured through discipline. When patients tell me the food noise went quiet, that's the neurological piece, not just the stomach.

A 2025 study by Zheng and colleagues in European Psychiatry tried to untangle how much of the mood effect comes from the drug versus from the weight loss itself. Using genetic instruments alongside a large adverse-event database, the authors found that weight loss partially mediated the relationship between these medications and both depression and emotional lability, accounting for roughly eighteen percent and eight percent of the total effect respectively. Their genetic analyses pointed toward reduced risk of anxiety, depression, and emotional lability rather than increased risk. So most of the benefit, by their read, is not simply "you lost weight and felt better." Something else is going on.

The Part Nobody Should Skip Over

I'd be doing you a disservice if I stopped there, because the literature is genuinely split, and any physician telling you these medications are unambiguously good for mood is not reading carefully.

A 2026 systematic review and meta-analysis by Bi and colleagues in BMC Psychiatry pooled nineteen studies and found an association between GLP-1 receptor agonist use and depression-related adverse events, with an odds ratio of 1.49. That sounds alarming until you look at the heterogeneity, which they reported at over ninety-nine percent. In plain terms, the studies they combined disagreed with each other almost completely. When heterogeneity is that extreme, the pooled number is less a finding than a flag. The authors said as much, concluding that the risk appeared to be dominated by which population was studied, which drug was used, and how mood was measured in the first place. Their recommendation was caution in patients with psychiatric history and better-designed studies with mood as a primary endpoint. I think that's exactly right.

A separate 2025 systematic review by Meshkat and colleagues in Brain and Behavior looked at twenty-six studies covering about three thousand patients and reached a similarly unsettled conclusion. Liraglutide improved depression and anhedonia scores in mood disorder patients. Other agents produced mixed or null results. Of the nine randomized controlled trials they included, three showed a significant effect on the primary psychiatric outcome and six did not. Their word for the overall picture was "inconclusive."

So where does that leave us? With a signal worth watching and not worth panicking about. In my practice I treat mood the way I treat any other monitorable parameter on these medications. I ask about it at baseline, I ask about it at every follow-up, and I don't wait for a patient to volunteer that something feels off. If someone has a history of depression, that isn't automatically a reason to avoid a GLP-1. It's a reason to watch more closely and to make sure their psychiatric care is actually active rather than theoretical.

The Mood Complaints I Actually See

Here's what I've learned after enough of these consults: when a patient on a GLP-1 medication reports that their mood has gotten worse, the cause is usually mechanical, and usually fixable.

• They're eating far too little. This is the big one. When appetite disappears, some patients drift down to six or seven hundred calories a day without noticing. That's not a diet. That's a semi-starvation state, and semi-starvation reliably produces irritability, apathy, and low mood in people with no psychiatric history whatsoever. We've known this since the Minnesota Starvation Experiment in the 1940s.
• Protein has collapsed. Protein is the first thing to go when food stops being appealing, because it's the most work to eat. Inadequate protein means inadequate amino acid substrate for neurotransmitter synthesis, on top of the muscle loss we're already fighting.
• They're dehydrated. Thirst cues get muddled along with hunger cues, and in a Texas August that adds up fast. Mild dehydration alone measurably worsens mood and concentration.
• Sleep is fragmented. Nausea and reflux from delayed gastric emptying, especially with a late dinner, wreck sleep quality. Bad sleep is bad mood. That one isn't complicated.
• Micronutrients have slipped. Less food means less iron, B12, vitamin D, and magnesium, all of which show up as fatigue and low mood well before anything shows up as a deficiency on paper.
• Food was doing a job nobody replaced. This is the one we talk about least and it matters most. If eating was how you decompressed after a hard day, and the medication removed eating, the hard day is still there. The coping mechanism left and nothing moved into the vacancy.

Notice that not one of those is the drug acting directly on the brain to cause depression. They're all downstream consequences of eating less, and they're all addressable without stopping treatment.

How We Keep Mood Steady

What I tell my patients is that appetite suppression is a tool, not a target. The goal was never to eat as little as humanly possible.

We set floors. A calorie floor, which for most of my patients lands somewhere between 1,200 and 1,500 depending on size and sex, and a protein floor of roughly 100 to 140 grams a day. Those aren't suggestions. If you can't hit them because nothing sounds good, that's information, and it usually means we're titrating faster than your body wants to go. Slowing the dose escalation fixes more mood complaints than any supplement I could hand you.

We screen before we start. I ask about depression and anxiety history, current treatment, and what happened during past weight loss attempts, because the person who got depressed on a previous restrictive diet is telling me something useful about how they respond to a deficit. We check labs at baseline and along the way, including thyroid, iron studies, B12, and vitamin D, since all of those masquerade as mood problems.

And we treat mood as a real endpoint, not a side conversation. Weight is easy to measure and therefore easy to over-focus on. If the scale is moving and you feel terrible, that's not success, and I'd rather back off the dose and keep you on treatment for two years than push hard and lose you in four months. Our semaglutide program is built around that kind of monitoring, and the broader picture is laid out in our guide to physician-supervised GLP-1 weight loss in DFW.

Most of my patients experience the mood side of these medications as a relief. The constant negotiation with food goes quiet, blood sugar stops whipsawing, and the 4 p.m. edge softens. But that outcome isn't automatic, and it's not something you should have to figure out alone from a telehealth prescription and a shipping label. If your mood has gotten worse since starting a GLP-1, or if it got better and then slid, that's worth a real conversation with a physician who's watching more than your weight. That's the work we do every day at Magnolia Functional Wellness here in Southlake, and it starts with actually asking how you feel.